Merck, Inc.
🇺🇸United States
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Phase 3
Completed
- Conditions
- Nasopharyngeal Neoplasms
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 233
- Registration Number
- NCT02611960
Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02601573
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Phase 3
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 310
- Registration Number
- NCT02579863
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
Phase 3
Completed
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Dietary Supplement: Folic acid 350-1000 μgDietary Supplement: Vitamin B12 1000 μgDrug: Saline solution
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 616
- Registration Number
- NCT02578680
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 141
- Registration Number
- NCT02577016
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Phase 3
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 251
- Registration Number
- NCT02576977
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT02577003
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Phase 2
Completed
- Conditions
- Mediastinal Large B-cell LymphomaRichter Syndrome
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT02576990
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
Phase 3
Completed
- Conditions
- Anogenital Human Papilloma Virus InfectionCondyloma Acuminata
- Interventions
- Biological: V501
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02576054
- Locations
- 🇯🇵
MSD K.K., Chiyoda-Ku, Tokyo, Japan
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
Phase 2
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Prevnar 13™Biological: V114
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 253
- Registration Number
- NCT02573181
© Copyright 2025. All Rights Reserved by MedPath